Seminars in Nuclear Medicine
Volume 40, Issue 2 , Pages 78-88 , March 2010

Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors

  • Dik J. Kwekkeboom, MD, PhD

      Affiliations

    • Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    • Corresponding Author InformationAddress reprint requests to Dik J. Kwekkeboom, MD, PhD, Department Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 Rotterdam, The Netherlands
    • ,
  • Wouter W. de Herder, MD, PhD

      Affiliations

    • Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    • ,
  • Casper H.J. van Eijck, MD, PhD

      Affiliations

    • Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands
    • ,
  • Boen L. Kam, MD

      Affiliations

    • Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    • ,
  • Martijn van Essen, MD

      Affiliations

    • Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    • ,
  • Jaap J.M. Teunissen, MD, PhD

      Affiliations

    • Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    • ,
  • Eric P. Krenning, MD, PhD

      Affiliations

    • Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

References 

  1. Krenning EP, Bakker WH, Breeman WA, et al. Localization of endocrine related tumors with radioiodinated analogue of somatostatin. Lancet. 1989;1:242–245
  2. Arnold R, Benning R, Neuhaus C, et al. Gastroenteropancreatic endocrine tumours: Effect of Sandostatin on tumour growth (The German Sandostatin Study Group). Digestion. 1993;54(suppl 1):72–75
  3. Janson ET, Oberg K. Long-term management of the carcinoid syndrome (Treatment with octreotide alone and in combination with alpha-interferon). Acta Oncol. 1993;32:225–229
  4. Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000;95:3276–3281
  5. Valkema R, de Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The Rotterdam experience. Semin Nucl Med. 2002;32:110–122
  6. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):62S–66S
  7. Anthony LB, Woltering EA, Espanan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123–132
  8. Waldherr C, Pless M, Maecke HR, et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol. 2001;12:941–945
  9. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43:610–616
  10. Waldherr C, Schumacher T, Maecke HR, et al. Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors?. (abstract) Eur J Nucl Med Mol Imaging. 2002;29(suppl 1):S100
  11. Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging. 2003;30:207–216
  12. Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147–156
  13. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–2130
  14. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med. 1999;26:1439–1447
  15. Chinol M, Bodei L, Cremonesi M, et al. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: The experience of the European Institute of Oncology group. Semin Nucl Med. 2002;32:141–147
  16. Paganelli G, Bodei L, Handkiewicz Junak D, et al. 90Y-DOTA-D-Phe1–Tyr3-octreotide in therapy of neuroendocrine malignancies. Biopolymers. 2002;66:393–398
  17. Valkema R, Pauwels S, Kvols L, et al. Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with [90Y-DOTA0, Tyr3]octreotide in patients with somatostatin receptor positive tumours (abstract). Eur J Nucl Med Mol Imaging. 2003;30(suppl 2):S232
  18. Bushnell D, O'Dorisio T, Menda Y, et al. Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med. 2003;44:1556–1560
  19. de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998;58:437–441
  20. Erion JL, Bugaj JE, Schmidt MA, et al. High radiotherapeutic efficacy of [Lu-177]-DOTA-Y(3)-octreotate in a rat tumor model (abstract). J Nucl Med. 1999;40(suppl):223
  21. Reubi JC, Schaer JC, Waser B, et al. Affinity profiles for human somatostatin receptor SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–282
  22. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [177Lu-DOTA0Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28:1319–1325
  23. Esser JP, Krenning EP, Teunissen JJ, et al. Comparison of [(177)Lu-DOTA(0), Tyr(3)]octreotate and [(177)Lu-DOTA(0), Tyr(3)]octreotide: Which peptide is preferable for PRRT?. Eur J Nucl Med Mol Imaging. 2006;33:1346–1351
  24. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417–422
  25. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Treatment with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate in patients with gastro-entero-pancreatic (GEP) tumors. J Clin Oncol. 2005;23:2754–2762
  26. De Keizer B, van Aken MO, Feelders RA, et al. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2008;35:749–755
  27. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol. 2004;22:2724–2729
  28. Virgolini I, Britton K, Buscombe J, et al. 111In- and 90Y-DOTA-Lanreotide: Results and implications of the Mauritius trial. Semin Nucl Med. 2002;32:148–155
  29. Wehrmann C, Senftleben S, Zachert C, et al. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22:406–416
  30. Baum RP, Soldner J, Schmucking M, et al. Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren Klinischen Indikationen und Erfahrung mit 90Yttrium-markierten Somatostatinanaloga. Der Onkologe. 2004;10:1098–1110
  31. Baum RP, Soldner J, Schmucking M, et al. Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumors (abstract). Eur J Nucl Med. 2004;31(suppl 2):S238
  32. Clancy TE, Sengupta TP, Paulus J, et al. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006;51:877–884
  33. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8:685–690
  34. Quaedvlieg PF, Visser O, Lamers CB, et al. Epidemiology and survival in patients with carcinoid disease in the Netherlands (An epidemiological study with 2391 patients). Ann Oncol. 2001;12:1295–1300
  35. Mazzaglia PJ, Berber E, Milas M, et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: A 10-year experience evaluating predictors of survival. Surgery. 2007;142:10–19
  36. Faiss S, Pape UF, Bohmig M, et al. International Lanreotide and Interferon Alfa Study Group: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689–2696
  37. Bukowski RM, Tangen CM, Peterson RF, et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. Cancer. 1994;73:1505–1508
  38. Ritzel U, Leonhardt U, Stockmann F, et al. Treatment of metastasized midgut carcinoids with dacarbazine. Am J Gastroenterol. 1995;90:627–631
  39. Andreyev HJ, Scott-Mackie P, Cunningham D, et al. Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol. 1995;13:1486–1492
  40. Neijt JP, Lacave AJ, Splinter TA, et al. Mitoxantrone in metastatic apudomas: A phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group. Br J Cancer. 1995;71:106–108
  41. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer. 1999;86:944–948
  42. Ansell SM, Pitot HC, Burch PA, et al. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer. 2001;91:1543–1548
  43. O'Toole D, Hentic O, Corcos O, et al. Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology. 2004;80(suppl 1):79–84
  44. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Eng J Med. 1980;303:1189–1194
  45. Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol. 1993;1:727–740
  46. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–523
  47. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:4762–4771
  48. Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol. 2005;23:4897–4904
  49. Ducreux MP, Boige V, Leboulleux S, et al. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas. Oncology. 2006;70:134–140
  50. Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. Cancer Chemother Pharmacol. 2007;59:637–642
  51. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13:2986–2991
  52. Strosberg JR, Choi J, Gardner N, et al. First-line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide (abstract). J Clin Oncol. 2008;26(suppl):4612
  53. Kulke MH, Stuart K, Earle CC, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors (abstract). J Clin Oncol. 2006;24(suppl):4044
  54. Hobday TJ, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study (abstract). J Clin Oncol. 2007;25(suppl):4504
  55. Yao JC, Zhang JX, Rashid A, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007;13:234–240
  56. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403–3410
  57. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006;95:1148–1154
  58. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol. 2008;26:4311–4318
  59. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med. 2002;32:133–140
  60. Wong JY, Shibata S, Williams LE, et al. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003;9:5842–5852
  61. Kong G, Lau E, Ramdave S, et al. High-dose In-111 octreotide therapy in combination with radiosensitizing 5-FU chemotherapy for treatment of SSR-expressing neuroendocrine tumors (abstract). J Nucl Med. 2005;46(suppl 2):151P
  62. Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: Current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol. 2004;22:2214–2232
  63. Dunst J, Reese T, Sutter T, et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol. 2002;20:3983–3991
  64. Van Essen M, Krenning EP, Kam BL, et al. Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:743–748
  65. Förrer F, Krenning EP, Kooij PP, et al: Bone marrow dosimetry in peptide receptor radionuclide therapy with [(177)Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging (in press)
  66. Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177) (Lu-DOTA(0), Tyr(3)-octreotate). J Nucl Med. 2005;46(suppl 1):83S–91S
  67. Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–1856
  68. Konijnenberg M, Melis M, Valkema R, et al. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med. 2007;48:134–142

PII: S0001-2998(09)00102-0

doi: 10.1053/j.semnuclmed.2009.10.004

Seminars in Nuclear Medicine
Volume 40, Issue 2 , Pages 78-88 , March 2010

Article Tools

* Image Usage & Resolution